STAT+: RevMed’s pancreatic cancer drug nears European approval

RegulatoryRasonquePositive

AI Analysis

Summary

European regulators have recommended approval of Revolution Medicines' Rasonque for pancreatic cancer, following an earlier FDA approval. The recommendation brings the drug closer to European market authorization.

Outcome Details

European regulators recommended approval of Rasonque for pancreatic cancer, following a prior FDA approval.

Importance:7/10

Sentiment:

0.80

EMACHMPpancreatic canceroncologyregulatoryEurope

Related Companies

$RVMD

Read the original article

Published by STAT News on October 16, 2026 1:38 PM

Read Original